EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma

Hiromi Nagano iD, Satoshi Kiyama iD, Takayuki Kyutoku iD, Masaru Yamashita iD

The Laryngoscope · 2026-12 · 136 (12) · 5599-5605

DOI: 10.1002/lary.70842 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 17.08.2026. Verfasst von Hiromi Nagano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Mutation, Thyroid Cancer, Papillary, Neoplasm Recurrence, Local. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The purpose of this study is to investigate the genetic mutational status of recurrent/metastatic papillary thyroid carcinoma (PTC) and its prognostic implications.

Methods

Data were analyzed for 348 consecutive patients with PTC registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) between June 2019 and February 2026. Genetic mutations were determined by next generation sequencing. Survival of patients was determined by log‐rank test and a Cox proportional hazards model.

Results

The top 10 mutations in recurrent/metastatic PTC were TERT (82.2%), BRAF (78.7%), LTK (16.1%), CDKN2A (15.2%), KMT2D (14.4%), NOTCH3 (14.1%), TP53 (12.9%), PIK3CA (11.5%), CDKN2B (10.6%), STK11 (10.3%), with 11.0 ± 0.19 (mean ± SEM) mutations/individual. BRAF ( p = 0.0379), CDKN2A ( p = 7.41 × 10 −12 ), KMT2D ( p = 0.0048), PIK3CA ( p = 0.0406), CDKN2B ( p = 7.24 × 10 −13 ), and concurrent TERT/BRAF ( p = 0.0141) were associated with a significantly worse prognosis, as determined by log‐rank test. Multivariable Cox proportional hazards analysis was 3.762 (95% CI, 1.7480–8.095; p = 7.026 × 10 −4 ) for CDKN2A , 2.620 (1.50–4.575; p = 7.076 × 10 −4 ) for KMT2D, 1.882 (1.127–3.143; p = 0.01572) for concurrent TERT/BRAF .

Conclusions

This study delineated the mutational spectrum of recurrent and/or metastatic PTC and identified several alterations with significant prognostic relevance. Even in advanced disease, specific mutations such as CDKN2A , KMT2D , and concurrent TERT/BRAF remained strongly associated with poor survival, underscoring the clinical value of comprehensive cancer genomic profiling in this population. Level of Evidence 3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsMutationThyroid Cancer, PapillaryNeoplasm Recurrence, LocalHumansFemalePrognosisMaleMiddle AgedAdultProto-Oncogene Proteins B-rafAgedJapanHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

CDKN2AKMT2Dconcurrent TERT/BRAFgenetic mutationspapillary thyroid carcinoma

Substanzen

Proto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

ORCID-Profile: Hiromi Nagano, Satoshi Kiyama, Takayuki Kyutoku, Masaru Yamashita

Zitieren

APA

Nagano, H., Kiyama, S., Kyutoku, T., & Yamashita, M. (2026). Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma. The Laryngoscope, 136(12), 5599-5605. https://doi.org/10.1002/lary.70842

Vancouver

Nagano H, Kiyama S, Kyutoku T, Yamashita M. Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma. The Laryngoscope. 2026;136(12):5599-5605. doi:10.1002/lary.70842

BibTeX
@article{Nagano2026,
  author = {Nagano, Hiromi and Kiyama, Satoshi and Kyutoku, Takayuki and Yamashita, Masaru},
  title = {Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma},
  journal = {The Laryngoscope},
  year = {2026},
  volume = {136},
  number = {12},
  pages = {5599--5605},
  doi = {10.1002/lary.70842}
}
Kostenlos starten →